Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. More Details
Excellent balance sheet and good value.
Share Price & News
How has Integrated Diagnostics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IDGX.F's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IDGX.F underperformed the US Healthcare industry which returned 15.9% over the past year.
Return vs Market: IDGX.F underperformed the US Market which returned 13.6% over the past year.
Price Volatility Vs. Market
How volatile is Integrated Diagnostics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Integrated Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IDGX.F ($3.95) is trading below our estimate of fair value ($10.46)
Significantly Below Fair Value: IDGX.F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IDGX.F is good value based on its PE Ratio (19.1x) compared to the US Healthcare industry average (22.4x).
PE vs Market: IDGX.F is poor value based on its PE Ratio (19.1x) compared to the US market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: IDGX.F is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: IDGX.F is overvalued based on its PB Ratio (3.7x) compared to the US Healthcare industry average (2.9x).
How is Integrated Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDGX.F's forecast earnings growth (19.8% per year) is above the savings rate (2.2%).
Earnings vs Market: IDGX.F's earnings (19.8% per year) are forecast to grow slower than the US market (23.2% per year).
High Growth Earnings: IDGX.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: IDGX.F's revenue (14.9% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: IDGX.F's revenue (14.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDGX.F's Return on Equity is forecast to be high in 3 years time (29%)
How has Integrated Diagnostics Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDGX.F has high quality earnings.
Growing Profit Margin: IDGX.F's current net profit margins (22%) are lower than last year (24.1%).
Past Earnings Growth Analysis
Earnings Trend: IDGX.F's earnings have grown significantly by 24.7% per year over the past 5 years.
Accelerating Growth: IDGX.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IDGX.F had negative earnings growth (-8.6%) over the past year, making it difficult to compare to the Healthcare industry average (31.1%).
Return on Equity
High ROE: IDGX.F's Return on Equity (18.2%) is considered low.
How is Integrated Diagnostics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IDGX.F's short term assets (EGP1.1B) exceed its short term liabilities (EGP674.8M).
Long Term Liabilities: IDGX.F's short term assets (EGP1.1B) exceed its long term liabilities (EGP607.7M).
Debt to Equity History and Analysis
Debt Level: IDGX.F's debt to equity ratio (4.1%) is considered satisfactory.
Reducing Debt: IDGX.F's debt to equity ratio has increased from 0% to 4.1% over the past 5 years.
Debt Coverage: IDGX.F's debt is well covered by operating cash flow (595.9%).
Interest Coverage: IDGX.F's interest payments on its debt are well covered by EBIT (66x coverage).
What is Integrated Diagnostics Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IDGX.F's dividend (4.95%) is higher than the bottom 25% of dividend payers in the US market (1.66%).
High Dividend: IDGX.F's dividend (4.95%) is in the top 25% of dividend payers in the US market (4.68%)
Stability and Growth of Payments
Stable Dividend: IDGX.F has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: IDGX.F's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (97.2%), IDGX.F's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: IDGX.F's dividends in 3 years are forecast to be covered by earnings (83.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Hend El Sherbini (51 yo)
Prof. Dr. Hend El Sherbini has been Group Chief Executive Officer of Integrated Diagnostics Holdings plc since 2012 and as its Executive Director since December 23, 2014. Prof. Dr. El Sherbini serves as th ...
CEO Compensation Analysis
Compensation vs Market: Hend's total compensation ($USD601.91K) is below average for companies of similar size in the US market ($USD2.02M).
Compensation vs Earnings: Hend's compensation has been consistent with company performance over the past year.
|Group CEO & Executive Director||8.67yrs||ج.م9.48m||25.5% |
|Independent Non-Executive Chairman||5.67yrs||ج.م1.23m||no data|
|Non-Executive Director||5.75yrs||no data||no data|
|Independent Non-Executive Director||5.42yrs||ج.م981.45k||no data|
|Independent Non-Executive Director||5.67yrs||ج.م462.08k||no data|
|Independent Non-Executive Director||5.67yrs||ج.م899.66k||no data|
Experienced Board: IDGX.F's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Integrated Diagnostics Holdings plc's company bio, employee growth, exchange listings and data sources
- Name: Integrated Diagnostics Holdings plc
- Ticker: IDGX.F
- Exchange: OTCPK
- Founded: 1979
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$566.250m
- Shares outstanding: 150.00m
- Website: https://www.idhcorp.com
Number of Employees
- Integrated Diagnostics Holdings plc
- 12 Castle Street
- Saint Helier
- JE2 3RT
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IDHC||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||USD||May 2015|
|IDHCL||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||USD||May 2015|
|IDGX.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||May 2015|
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 1,400 diagnostic test services, including immunology, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/19 06:10|
|End of Day Share Price||2020/09/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.